13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001444043
Total reported value
$1.1B
$1.1B
33 檔
142.0%
During the Q3 2024 filing period, Camber Capital Management LP (CIK: 0001444043) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $1.1B across 33 reported positions.
During Q3 2024, Camber Capital Management LP's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | SPY | Ss Spdr S&p 500 ETF Trust-us | ETF-Large Cap & Growth | 18.22% | — | -42.86% | |
| 2 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 8.57% | — | +29.87% | |
| 3 | MDT | Medtronic plc | Stock-Healthcare | 7.86% | — | +22.22% | |
| 4 | BAX | Baxter International Inc | Stock-Healthcare | 7.84% | — | +18.18% | |
| 5 | VTRS | Viatris Inc | Stock-Healthcare | 5.53% | — | — | |
| 6 | GMED | Globus Medical Inc - A | Stock-Healthcare | 4.89% | — | -14.00% | |
| 7 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 4.12% | — | — | |
| 8 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 4.07% | — | — | |
| 9 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 3.90% | — | +12.15% | |
| 10 | MYGN | Myriad Genetics Inc | Stock-Other | 3.44% | — | -28.18% | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 3.32% | — | — | |
| 12 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 3.07% | — | +416.67% | |
| 13 | BKD | Brookdale Senior Living Inc | Stock-Other | 3.01% | — | -10.10% | |
| 14 | CVS | Cvs Health CORP | Stock-Healthcare | 3.00% | — | — | |
| 15 | SEM | Select Medical Holdings CORP | Stock-Other | 2.35% | — | -16.67% | |
| 16 | QGEN | Qiagen N.V. | Stock-Healthcare | 2.17% | — | — | |
| 17 | HUM | Humana Inc | Stock-Healthcare | 2.01% | — | -50.00% | |
| 18 | DNLI | Denali Therapeutics Inc | Stock-Other | 1.85% | — | — | |
| 19 | CON | Concentra Group Holdings Par | Stock-Other | 1.40% | — | — | |
| 20 | ZIMV | Zimvie Inc | Stock-Other | 1.37% | — | -16.15% | |
| 21 | MEDP | Medpace Holdings Inc | Stock-Healthcare | 1.33% | — | — | |
| 22 | EVH | Evolent Health Inc - A | Stock-Other | 1.26% | — | +124.00% | |
| 23 | UHS | Universal Health Services-b | Stock-Healthcare | 0.91% | — | -86.84% | |
| 24 | BKD 7 11-15-25Bond | Brookdale Senior Living | Bond | 0.73% | — | — | |
| 25 | MLTX | Moonlake Immunotherapeutics | Stock-Other | 0.71% | — | +24.23% | |
| 26 | HLF | Herbalife Ltd. | Stock-Other | 0.69% | — | — | |
| 27 | BCYC | Bicycle Therapeutics Plc-adr | Stock-Other | 0.66% | — | — | |
| 28 | INGN | Inogen Inc | Stock-Other | 0.62% | — | — | |
| 29 | OSUR | Orasure Technologies Inc | Stock-Other | 0.58% | — | — | |
| 30 | TBPH | Theravance Biopharma, Inc. | Stock-Other | 0.26% | — | — | |
| 31 | ALKS | Alkermes plc | Stock-Healthcare | 0.18% | — | — | |
| 32 | SKIN | Skinhealth Systems Inc | Stock-Other | 0.07% | — | -57.14% | |
| 33 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.04% | — | — |
According to official SEC Form 13F filings, Camber Capital Management LP reported a total U.S. public equity portfolio value of $1.1B across 33 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including SPY, ZBH, MDT) accounted for 142.0% of total reported equity market value during Q3 2024.
During Q3 2024, Camber Capital Management LP's top holdings by market value included SPY (18.2%)、ZBH (8.6%)、MDT (7.9%). The largest single position, SPY, represented 18.2% of total portfolio value.
In Q3 2024, Camber Capital Management LP made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.